AtaiBeckley continued advancing its clinical pipeline with promising updates for BPL-003 and EMP-01. Despite increasing R&D and G&A expenses contributing to a higher net loss, the company bolstered its balance sheet through a $150 million public offering, extending its cash runway into 2029.

Atai Life Sciences reduced its net loss to $27.7 million in Q2 2025 and posted $719,000 in revenue, while advancing key clinical programs including BPL-003 and VLS-01. The company strengthened its financial position and continued progressing strategic milestones.

Atai Life Sciences reported a net loss of $38.99 million for Q4 2024. The company's cash and equivalents decreased to $17.5 million, while research and development expenses rose to $18.94 million. Despite these financial challenges, the company continues progressing with its clinical trials, with topline data from key studies expected in 2025 and 2026.

Atai Life Sciences reported a net loss of $26.3 million for the third quarter of 2024. The company's cash, cash equivalents, and short-term securities totaled $101.0 million as of September 30, 2024, expected to fund operations into 2026.

Atai Life Sciences reported its Q2 2024 financial results, highlighting advancements in its pipeline with positive Phase 1b results for VLS-01 and progress in EMP-01 clinical development. The company's cash, marketable securities, and committed term loan funding are expected to fund operations into 2026. R&D expenses decreased compared to the same period last year, while G&A expenses also saw a reduction. Net loss attributable to stockholders was $57.3 million, compared to $33.0 million for the same period in 2023.

Atai Life Sciences reported a net loss of $26.7 million for the first quarter of 2024, compared to a net loss of $33.1 million for the same period in 2023. The company's cash, marketable securities, and committed term loan funding are expected to fund operations into 2026. Atai is also undergoing a leadership transition with Florian Brand stepping down as CEO and Srinivas Rao to take over.

Atai Life Sciences reported Q4 2023 financial results, highlighting a net loss of $18.3 million and R&D expenses of $14.2 million. The company is focused on developing psychedelic-based therapies for mental health disorders and anticipates several clinical milestones in the coming year.

Atai Life Sciences reported a net income of $44.2 million for Q3 2023, driven by a non-cash change in the fair value of investments. The company highlighted progress in its clinical programs, including the ongoing Phase 2b study of RL-007 and Phase 1 results from the VLS-01 study.

Atai Life Sciences reported a net loss of $33.1 million for the three months ended June 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $227.5 million as of June 30, 2023, expected to fund operations into 1H 2026.

Atai Life Sciences reported a net loss of $33.1 million for the first quarter of 2023. The company's cash and cash equivalents totaled $249.9 million as of March 31, 2023, which is expected to fund operations into 1H 2026.

Atai Life Sciences reported its fourth quarter and full year 2022 financial results, highlighting its clinical pipeline advancements and a cash runway into the first half of 2026. The company's cash, cash equivalents, and short-term investments totaled $273.1 million at the end of 2022.

Atai Life Sciences reported its Q3 2022 financial results, highlighting advancements in its clinical programs, including the dosing of the final patient in the Phase 2a trial of PCN-101 for TRD and positive results from Phase 1 studies of GRX-917 and KUR-101. The company ended the quarter with $304.1 million in cash and is anticipated to have cash runway into 2025.

Atai Life Sciences reported a strong cash position of $312 million at the end of Q2 2022, further strengthened by a non-dilutive term loan facility of up to $175 million. The company has taken actions to extend its anticipated runway by one year into 2025 and anticipates realizing significant cost savings from a company-wide cost optimization.

Atai Life Sciences reported a net loss attributable to shareholders of $36.9 million for the three months ended March 31, 2022. The company ended the quarter with $335 million in cash and cash equivalents.

Atai Life Sciences ended 2021 with a strong cash position of $362 million. The company anticipates at least 14 drug development and enabling technology catalysts over the next two years. They are focused on rapid acting intervention, ongoing digital support and a biomarker-driven precision mental health.

atai Life Sciences reported its Q3 2021 financial results, highlighting positive momentum after its IPO in June with 11 therapeutic programs underway. The company saw positive Phase 2b data from COMPASS Pathways and initiated two new clinical trials. Atai also launched atai Impact, a philanthropic program to support innovative mental health approaches.